Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 12/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | FLT1 | P17948 | 3/20 | 0.35 |
| ▸ | FLT4 | P35916 | 3/20 | 0.35 |
| ▸ | KDR | P35968 | 3/20 | 0.35 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29621097 | 1.00 | DGAT1 (0.38) | DGAT1CHEK1JAK2JAK1FLT1 | |
| SCHEMBL29620981 | 0.86 | FLT1 (0.44) | DGAT1CHEK1FLT1FLT4KDR | |
| SCHEMBL22925978 | 0.86 | FLT1 (0.44) | DGAT1CHEK1FLT1FLT4KDR | |
| SCHEMBL22925742 | 0.82 | CHEK1 (0.40) | CHEK1FLT1FLT4KDRIMPDH2 | |
| SCHEMBL29620891 | 0.82 | CHEK1 (0.40) | CHEK1FLT1FLT4KDRIMPDH2 | |
| SCHEMBL22925918 | 0.81 | VCP (0.44) | CHEK1FLT1FLT4KDRIMPDH2 | |
| SCHEMBL22925932 | 0.79 | CHEK1 (0.39) | CHEK1FLT1FLT4KDRIMPDH2 | |
| SCHEMBL29620907 | 0.78 | MEN1 (0.40) | CHEK1FLT1FLT4KDRIMPDH2 | |
| SCHEMBL28733613 | 0.78 | MEN1 (0.40) | CHEK1FLT1FLT4KDRIMPDH2 | |
| SCHEMBL22925546 | 0.77 | DGAT1 (0.38) | DGAT1FLT1FLT4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220274970-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2022-09-01 | — | — | US | disclosed |
| CN-114450281-A | Inhibitor compounds | 辛塞拉治疗私人有限公司 | 2022-05-06 | — | — | CN | disclosed |
| WO-2021012018-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220274970-A1 | INHIBITOR COMPOUNDS | SERPINB1, MMP1, SSB | DGAT1 164/4885CHEK1 1509/4885JAK2 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.